Abemaciclib

Neuroblastoma, Recurrent, Refractory

Emory UniversitySmall moleculePhase 1Dormant

CC

47/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 95/ 100

Competitive context

63 Active assets in the Neuroblastoma, Recurrent, Refractory cohort.

Asset / Sponsor	Phase	Rating
Irinotecan National Cancer Institute (NCI)	Phase 2	BB
FILGRASTIM M.D. Anderson Cancer Center	Phase 4	BB
ETOPOSIDE M.D. Anderson Cancer Center	Phase 2/3	BB
Eloxatin National Cancer Institute (NCI)	Phase 2	BB
Cyclophosphamide Robbie Majzner	Phase 2	BB

View all 50 →

Same molecule, other indications

Abemaciclib is also rated in:

hormone receptor-positive breast cancerDormant

BBB

Indicative ·

72 / 100

estrogen-receptor positive breast cancerDormant

BB

Indicative ·

70 / 100

Hormone Receptor Positive TumorDormant

BB

Indicative ·

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.